- Identifier
- DBSNPE005527
- Drug
- Acetylsalicylic acid (DB00945)
- Interacting Gene/Enzyme
- Cytochrome P450 2C9
- Gene Name
- CYP2C9
- UniProt ID
- P11712
- Defining Change(s)
- Allele Name
- CYP2C9*11
- Genotype(s)
- Not Available
- Type(s)
- Effect Inferred
- Groups
- Decreased CYP2C9
- Description
- Poor drug metabolizer, lower dose requirements
- References
- Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [Article]
- Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [Article]
- King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [Article]
- Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [Article]
- The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]